Sucralfate NDC 42291-936

NDC codes

FDA NDC Directory

Product NDC (as listed)42291-936Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42291-0936Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42291-936-90	42291093690	90 TABLET in 1 BOTTLE (42291-936-90)Marketed from Oct 31, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate
Generic name (nonproprietary): sucralfate
Active ingredients: Sucralfate — 1 g/1
Dosage form: Tablet
Route: Oral
Labeler: AvKARE
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215576
Marketing start: Oct 31, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 42291-936_48c0e47e-08b1-0c73-e063-6394a90a90b7SPL ID 48c0e47e-08b1-0c73-e063-6394a90a90b7SPL set ID 0909acc5-c746-17fb-e063-6394a90a677fRxCUI 314234UNII XX73205DH5
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442291093690 followed by a unit qualifier and the quantity

Package 42291-0936-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 19, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate tablets are indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215576

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215576
Product	Strength	Form · route	Labeler	Product NDC
Sucralfate	Sucralfate 1 g/1	TabletOral	Amneal Pharmaceuticals NY LLC	60219-1656
Sucralfate	Sucralfate 1 g/1	TabletOral	Amneal Pharmaceuticals NY LLC	69238-1656